---
title: East-West Collaborative Medicine Using Bee-Venom Acupuncture on Whiplash-Associated Disorders
nct_id: NCT01369238
overall_status: UNKNOWN
phase: NA
sponsor: Korean Pharmacoacupuncture Institute
study_type: INTERVENTIONAL
primary_condition: Whiplash Injuries
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01369238.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01369238"
ct_last_update_post_date: 2011-06-08
last_seen_at: "2026-05-12T07:31:14.813Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# East-West Collaborative Medicine Using Bee-Venom Acupuncture on Whiplash-Associated Disorders

**Official Title:** Clinical Research on the Efficacy of East-West Collaborative Medicine Using Bee-Venom Acupuncture Therapy on Whiplash-Associated Disorders After Traffic Collisions; A Randomized, Controlled, Parallel Trial

**NCT ID:** [NCT01369238](https://clinicaltrials.gov/study/NCT01369238)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 90
- **Lead Sponsor:** Korean Pharmacoacupuncture Institute
- **Conditions:** Whiplash Injuries
- **Start Date:** 2011-06
- **Completion Date:** 2012-03
- **CT.gov Last Update:** 2011-06-08

## Brief Summary

1. Purpose of study

   1. To evaluate the efficacy of East-West collaborative medicine using Bee-Venom Acupuncture Therapy on Whiplash-Associated Disorders using VAS scale
   2. To evaluate the efficacy of East-West collaborative medicine using Bee-Venom Acupuncture Therapy on Whiplash-Associated Disorders using NDI, BDI, SF-36, and EQ-5D.
2. Interventions \& Groups

   1. group 1: Bee-Venom Acupuncture Therapy
   2. group 2: zaltoprofen
   3. group 3: Bee-Venom Acupuncture Therapy \& zaltoprofen

## Eligibility

- **Minimum age:** 25 Years
- **Maximum age:** 55 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* clinical diagnosis of Whiplash injuries
* Must have cervicalgia of more than VAS 5

Exclusion Criteria:

* cancer, osteoporosis, ankylosing spodylitis, cauda equina syndrome, infection
* spinal operation
* other musculoskeletal pain
* physicological or mental disorders
```

## Arms

- **Bee Venom Acupuncture & zaltoprofen** (EXPERIMENTAL)
- **zaltoprofen** (ACTIVE_COMPARATOR)
- **Bee Venom Acupuncture** (ACTIVE_COMPARATOR)

## Interventions

- **Bee Venom Acupuncture Therapy** (DEVICE) — 1:4000, SC 1cc/day, 2\~3days/wk, for 1 month
- **zaltoprofen** (DRUG) — 80mg/Tab, per os 1Tab tid, for 2 months

## Primary Outcomes

- **pain scores on Visual Analogue Scale** _(time frame: changes from baseline in VAS at 1 month)_

## Secondary Outcomes

- **neck disability scores on Neck Disability Index** _(time frame: changes from baseline in NDI at 1 month)_
- **depression scores on Beck Depression Inventory** _(time frame: changes from baseline in BDI at 1 month)_
- **quality of life scores on short form SF-36** _(time frame: changes from baseline in short form SF-36 at 1 month)_
- **quality of life scores on EQ-5D** _(time frame: changes from baseline in EQ-5D at 1 month)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01369238.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01369238*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*